Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P.
The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...
Dual-payload ADCs are gaining traction, offering opportunities to overcome the tumour heterogeneity and resistance challenges faced by conventional ADCs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback